Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Conditions: Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC) Interventions: Drug: AB598; Drug: Zimberelimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin Sponsor: Arcus Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Condition: Stage III Non-small Cell Lung Cancer Interventions: Drug: Toripalimab; Drug: JS004; Drug: Pemetrexed; Drug: Nab-paclitaxel; Drug: Carboplatin; Procedure: Surgery Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Conditions: Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC) Interventions: Drug: AB598; Drug: Zimberelimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin Sponsor: Arcus Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Condition: Stage III Non-small Cell Lung Cancer Interventions: Drug: Toripalimab; Drug: JS004; Drug: Pemetrexed; Drug: Nab-paclitaxel; Drug: Carboplatin; Procedure: Surgery Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Conditions: Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC) Interventions: Drug: AB598; Drug: Zimberelimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin Sponsor: Arcus Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Condition: Stage III Non-small Cell Lung Cancer Interventions: Drug: Toripalimab; Drug: JS004; Drug: Pemetrexed; Drug: Nab-paclitaxel; Drug: Carboplatin; Procedure: Surgery Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Conditions: Advanced Cancer; Advanced Malignancies; Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Head and Neck Squamous Cell Carcinoma (HNSCC); Non-Small Cell Lung Cancer (NSCLC); Ovarian Cancer; Renal Cell Carcinoma (RCC); Triple Negative Breast Cancer (TNBC) Interventions: Drug: AB598; Drug: Zimberelimab; Drug: Carboplatin; Drug: Pemetrexed; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin Sponsor: Arcus Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 6, 2023 Category: Research Source Type: clinical trials
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Condition: Non-small Cell Lung Cancer Interventions: Drug: SKB264; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin Sponsors: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2023 Category: Research Source Type: clinical trials
